Teikoku Seiyaku
Sanbonmatsu, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A 170-year-old Japanese pioneer in transdermal hydrogel patches, developing innovative pain management and systemic drug delivery solutions.
DermatologyNeurologyPain ManagementGeriatrics
Technology Platform
Proprietary Hydrohesive® transdermal drug delivery system enabling both localized and systemic medication delivery through hydrogel patches with controlled absorption.
Opportunities
Expansion of transdermal technology into new therapeutic areas beyond pain management, particularly neurological conditions and geriatric care, leveraging their proven Hydrohesive® platform and manufacturing scale.
Risk Factors
Dependence on patch technology platform, potential competition from newer drug delivery technologies, and challenges in expanding beyond traditional Japanese markets and pain management focus.
Competitive Landscape
Competes with transdermal specialists like Hisamitsu and diversified pharma companies with patch divisions; differentiates through proprietary hydrogel technology, systemic delivery capability, and prescription-focused innovation rather than OTC scale.